ArticleCureus2025
When Heart Failure Hides a Sarcoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac sarcomas are rare and highly aggressive primary cardiac tumors characterized by rapid growth, local invasion, and early metastasis, most commonly to the lungs, liver, and brain. Clinical presentation is nonspecific and largely depends on tumor location. Diagnosis relies on imaging, with transthoracic echocardiography as the first-line modality, while cardiac magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) provide complementary information for staging, surgical planning, and treatment monitoring. Surgical resection remains the cornerstone of therapy. Chemotherapy, radiotherapy, and emerging targeted or immunotherapies have shown limited benefit, highlighting the need for novel treatment strategies. We describe the case of a 71-year-old woman with multiple comorbidities, including heart failure with preserved ejection fraction, who presented with dyspnea, nocturnal breathlessness, edema, and cough. She was initially treated for decompensated heart failure with good short-term improvement. Echocardiography unexpectedly revealed a 50 × 30 mm left atrial mass infiltrating the mitral valve and septa, producing severe mitral stenosis and regurgitation. Cardiac MRI confirmed a sarcomatous lesion, considered unresectable due to extensive involvement. Staging CT identified an osteolytic lesion in the D12 vertebral body. A biopsy confirmed high-grade sarcoma, and PET showed no further spread. Given the rapid progression and recurrent heart failure, systemic therapy was not initiated, and the patient was transitioned to palliative care, passing away five months after diagnosis. This case highlights the diagnostic and therapeutic challenges of primary cardiac sarcomas. Primary cardiac sarcomas should be considered in patients with unexplained heart failure or intracardiac masses. Multidisciplinary management, improved systemic strategies, and timely palliative care are essential to address the aggressive biology and limited treatment options of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.